June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Consequences of Real-world Surveillance of Fellow Eyes in Neovascular Age-related Macular Degeneration
Author Affiliations & Notes
  • Oluchukwu Onwuka
    Ophthalmology, Lahey Hospital and Medical Center, Peabody, Massachusetts, United States
    Ophthalmology, Tufts University School of Medicine, Boston, Massachusetts, United States
  • Jackson Saddemi
    Rowan University Cooper Medical School, Camden, New Jersey, United States
  • F Sema Akkan
    Ophthalmology, Lahey Hospital and Medical Center, Peabody, Massachusetts, United States
    Ankara Sehir Hastanesi, Cankaya, Ankara, Turkey
  • Claudia Lasalle
    Ophthalmology, Lahey Hospital and Medical Center, Peabody, Massachusetts, United States
  • David J Ramsey
    Ophthalmology, Lahey Hospital and Medical Center, Peabody, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Oluchukwu Onwuka None; Jackson Saddemi None; F Akkan None; Claudia Lasalle None; David Ramsey None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 325 – F0156. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Oluchukwu Onwuka, Jackson Saddemi, F Sema Akkan, Claudia Lasalle, David J Ramsey; Consequences of Real-world Surveillance of Fellow Eyes in Neovascular Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2022;63(7):325 – F0156.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The aim of this study is to determine whether the interval at which fellow eyes are monitored impacts the severity of disease at the time of their conversion in patients with unilateral neovascular age-related macular degeneration (nAMD).

Methods : Cross sectional study of patients with unilateral nAMD who subsequently developed nAMD in their fellow eyes between March 2015 to October 2020. Patients were divided into those who were actively receiving treatment in their first eye at the time of second eye conversion and compared with those who had stopped treatment because of reaching end-stages of the disease. Visit intervals, frequency of monitoring fellow eyes, visual acuity (VA), and central macular thickness (CMT) were abstract from the chart.

Results : At the time of fellow eye conversion, 54 patients (71%) were receiving injections in their first eye and 22 patients (29%) had stopped treatment because of having low vision. VA in the first eyes to develop nAMD in the active treatment group was significantly better compared with the VA in eyes that had ceased treatment by the time of their conversion (logMAR 0.587±0.375 vs. logMAR 1.14±0.531, P<0.001). By contrast, VA was similar both at the time of diagnosis of the first eye (logMAR 0.384±0.436 vs. logMAR 0.367±0.328, P=0.867) and conversion of the fellow eye to nAMD (logMAR 0.492±0.412 vs. logMAR 0.465±0.400, P=0.795). The fellow eyes of patients who were actively receiving injections were monitored much more closely compared with those patients who had stopped treatment. At the visit immediately before second eye conversion, patients who were in the active treatment group had completed their last visit an average of 8.1±5.3 weeks compared with 25.5±24.8 weeks for those patients who had stopped treatment (P=0.004). Finally, the average CMT was similar for the fellow eyes that converted to nAMD in both groups (277±51 µm vs. 265±39 µm, P=0.305).

Conclusions : Patients who stopped treatment for nAMD by the time that their fellow eye developed neovascularization were monitored less frequently compared with patients who continued on treatment for nAMD. This is surprising because a majority of these patients were functionally monocular, and therefore had more to lose from the conversion of their remaining eye. Reassuring, however, visual and structural outcomes were not tied to the interval at which the fellow eyes were being monitored.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×